Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 8 | 2024 | 30 | 3.000 |
Why?
|
| Congenital Abnormalities | 7 | 2024 | 9 | 2.250 |
Why?
|
| Vagina | 10 | 2024 | 14 | 2.100 |
Why?
|
| Uterus | 7 | 2024 | 11 | 2.010 |
Why?
|
| Humans | 58 | 2024 | 4936 | 1.960 |
Why?
|
| Laparoscopy | 6 | 2024 | 10 | 1.600 |
Why?
|
| Mullerian Ducts | 6 | 2024 | 6 | 1.520 |
Why?
|
| Female | 27 | 2024 | 2523 | 1.320 |
Why?
|
| Cardiovascular Diseases | 4 | 2024 | 43 | 1.310 |
Why?
|
| Quality of Life | 3 | 2024 | 87 | 1.170 |
Why?
|
| Coronary Artery Disease | 3 | 2023 | 17 | 1.160 |
Why?
|
| Urogenital Abnormalities | 4 | 2024 | 4 | 1.160 |
Why?
|
| Stroke Volume | 6 | 2024 | 12 | 1.120 |
Why?
|
| Myocarditis | 3 | 2022 | 3 | 1.090 |
Why?
|
| Abnormalities, Multiple | 2 | 2023 | 2 | 0.980 |
Why?
|
| Myocardial Ischemia | 2 | 2023 | 3 | 0.980 |
Why?
|
| Cardiac Rehabilitation | 1 | 2024 | 1 | 0.880 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2024 | 9 | 0.880 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2024 | 1 | 0.870 |
Why?
|
| Vaginal Neoplasms | 1 | 2023 | 1 | 0.810 |
Why?
|
| Vaginal Fistula | 1 | 2023 | 1 | 0.800 |
Why?
|
| Myocardial Infarction | 4 | 2024 | 10 | 0.770 |
Why?
|
| Surgery, Plastic | 1 | 2022 | 1 | 0.770 |
Why?
|
| Trace Elements | 1 | 2022 | 1 | 0.760 |
Why?
|
| Round Ligament of Uterus | 1 | 2022 | 1 | 0.760 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 16 | 0.740 |
Why?
|
| Neoplasms | 1 | 2023 | 90 | 0.730 |
Why?
|
| Retrospective Studies | 13 | 2024 | 341 | 0.700 |
Why?
|
| Endoscopic Mucosal Resection | 1 | 2021 | 1 | 0.690 |
Why?
|
| Leiomyoma | 1 | 2021 | 1 | 0.690 |
Why?
|
| Polyps | 1 | 2021 | 1 | 0.690 |
Why?
|
| Myocardium | 1 | 2021 | 34 | 0.680 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 39 | 0.670 |
Why?
|
| 46, XX Disorders of Sex Development | 4 | 2024 | 4 | 0.650 |
Why?
|
| Aged | 7 | 2024 | 703 | 0.620 |
Why?
|
| Pregnancy | 6 | 2024 | 89 | 0.590 |
Why?
|
| Hospitalization | 5 | 2024 | 38 | 0.570 |
Why?
|
| Male | 12 | 2024 | 2491 | 0.560 |
Why?
|
| Aortic Valve Stenosis | 3 | 2022 | 3 | 0.530 |
Why?
|
| Transcatheter Aortic Valve Replacement | 3 | 2022 | 3 | 0.530 |
Why?
|
| Middle Aged | 8 | 2024 | 967 | 0.530 |
Why?
|
| Defibrillators, Implantable | 3 | 2021 | 3 | 0.530 |
Why?
|
| Cardiomyopathies | 3 | 2021 | 7 | 0.530 |
Why?
|
| Telemedicine | 3 | 2023 | 37 | 0.520 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2024 | 17 | 0.450 |
Why?
|
| Endometriosis | 2 | 2024 | 2 | 0.440 |
Why?
|
| Prospective Studies | 6 | 2024 | 111 | 0.430 |
Why?
|
| Live Birth | 2 | 2024 | 2 | 0.420 |
Why?
|
| Prevalence | 6 | 2024 | 66 | 0.420 |
Why?
|
| Cervix Uteri | 3 | 2022 | 7 | 0.420 |
Why?
|
| Premature Birth | 2 | 2024 | 3 | 0.410 |
Why?
|
| Hysterectomy | 2 | 2024 | 2 | 0.400 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2024 | 40 | 0.400 |
Why?
|
| Uterine Cervical Diseases | 2 | 2022 | 2 | 0.370 |
Why?
|
| Adult | 12 | 2024 | 1567 | 0.370 |
Why?
|
| Hypertension, Pulmonary | 2 | 2022 | 3 | 0.370 |
Why?
|
| Ventricular Function, Left | 4 | 2024 | 7 | 0.360 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 262 | 0.360 |
Why?
|
| Pacemaker, Artificial | 2 | 2021 | 4 | 0.360 |
Why?
|
| ST Elevation Myocardial Infarction | 2 | 2021 | 3 | 0.350 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2021 | 3 | 0.350 |
Why?
|
| Prognosis | 3 | 2023 | 60 | 0.290 |
Why?
|
| Cohort Studies | 6 | 2024 | 115 | 0.280 |
Why?
|
| Surgically-Created Structures | 2 | 2024 | 2 | 0.260 |
Why?
|
| Inflammasomes | 2 | 2024 | 40 | 0.250 |
Why?
|
| Biopsy | 2 | 2024 | 13 | 0.220 |
Why?
|
| Vitamin D Deficiency | 1 | 2024 | 3 | 0.220 |
Why?
|
| Dietary Supplements | 1 | 2024 | 6 | 0.220 |
Why?
|
| Vitamin D | 1 | 2024 | 4 | 0.220 |
Why?
|
| Walk Test | 1 | 2024 | 2 | 0.220 |
Why?
|
| Valsartan | 1 | 2024 | 1 | 0.220 |
Why?
|
| Metabolome | 1 | 2024 | 4 | 0.220 |
Why?
|
| Aminobutyrates | 1 | 2024 | 5 | 0.220 |
Why?
|
| Tetrazoles | 1 | 2024 | 4 | 0.220 |
Why?
|
| Biphenyl Compounds | 1 | 2024 | 7 | 0.220 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2024 | 4 | 0.220 |
Why?
|
| Abortion, Spontaneous | 1 | 2024 | 1 | 0.220 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 5 | 0.220 |
Why?
|
| Life Style | 1 | 2024 | 11 | 0.220 |
Why?
|
| Appendix | 1 | 2024 | 1 | 0.220 |
Why?
|
| Indocyanine Green | 1 | 2024 | 3 | 0.220 |
Why?
|
| Drug Combinations | 1 | 2024 | 25 | 0.220 |
Why?
|
| Heart Diseases | 2 | 2022 | 11 | 0.220 |
Why?
|
| Fertility | 1 | 2024 | 6 | 0.220 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2024 | 1 | 0.220 |
Why?
|
| Isoproterenol | 1 | 2024 | 3 | 0.210 |
Why?
|
| Adolescent | 6 | 2024 | 758 | 0.210 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 10 | 0.210 |
Why?
|
| Postpartum Hemorrhage | 1 | 2024 | 1 | 0.210 |
Why?
|
| Adenomyosis | 1 | 2024 | 1 | 0.210 |
Why?
|
| Fertilization | 1 | 2023 | 1 | 0.210 |
Why?
|
| United States | 2 | 2023 | 495 | 0.210 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2023 | 1 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 6 | 0.200 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2023 | 1 | 0.200 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 10 | 0.200 |
Why?
|
| Atherosclerosis | 1 | 2023 | 16 | 0.200 |
Why?
|
| Pregnancy, Twin | 1 | 2023 | 1 | 0.200 |
Why?
|
| Twins, Monozygotic | 1 | 2023 | 2 | 0.200 |
Why?
|
| Nitric Oxide Synthase | 1 | 2023 | 2 | 0.200 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2023 | 6 | 0.200 |
Why?
|
| Adenosine Triphosphate | 1 | 2023 | 19 | 0.200 |
Why?
|
| Colitis, Ulcerative | 1 | 2023 | 1 | 0.200 |
Why?
|
| Colon, Sigmoid | 1 | 2023 | 1 | 0.200 |
Why?
|
| Menopause | 1 | 2023 | 4 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 17 | 0.200 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2023 | 36 | 0.190 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2022 | 1 | 0.190 |
Why?
|
| Italy | 4 | 2024 | 6 | 0.190 |
Why?
|
| Vitamin A | 1 | 2022 | 1 | 0.190 |
Why?
|
| Vitamins | 1 | 2022 | 1 | 0.190 |
Why?
|
| Ligaments | 1 | 2022 | 1 | 0.190 |
Why?
|
| Pelvis | 1 | 2022 | 1 | 0.190 |
Why?
|
| Rectum | 1 | 2022 | 1 | 0.190 |
Why?
|
| Micronutrients | 1 | 2022 | 4 | 0.190 |
Why?
|
| Antioxidants | 1 | 2022 | 23 | 0.190 |
Why?
|
| Cesarean Section | 1 | 2022 | 3 | 0.190 |
Why?
|
| Microvascular Angina | 1 | 2022 | 1 | 0.190 |
Why?
|
| Hematocolpos | 1 | 2022 | 1 | 0.190 |
Why?
|
| Hematometra | 1 | 2022 | 1 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 197 | 0.190 |
Why?
|
| Vaginal Diseases | 1 | 2022 | 3 | 0.190 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2022 | 1 | 0.180 |
Why?
|
| Vena Cava, Superior | 1 | 2022 | 1 | 0.180 |
Why?
|
| Tachycardia, Ventricular | 1 | 2022 | 1 | 0.180 |
Why?
|
| Ventricular Premature Complexes | 1 | 2022 | 1 | 0.180 |
Why?
|
| Catheter Ablation | 1 | 2022 | 2 | 0.180 |
Why?
|
| Exercise | 1 | 2024 | 173 | 0.180 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2022 | 1 | 0.180 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 2 | 0.180 |
Why?
|
| Deprescriptions | 1 | 2022 | 3 | 0.180 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 2 | 0.180 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 16 | 0.180 |
Why?
|
| Oxidative Stress | 1 | 2022 | 58 | 0.180 |
Why?
|
| Electrocardiography | 1 | 2022 | 13 | 0.180 |
Why?
|
| Hospital Mortality | 1 | 2022 | 11 | 0.180 |
Why?
|
| Sodium | 1 | 2021 | 12 | 0.180 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 15 | 0.180 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 14 | 0.180 |
Why?
|
| Glucose | 1 | 2021 | 13 | 0.180 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 3 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 14 | 0.170 |
Why?
|
| Fibrosis | 1 | 2021 | 12 | 0.170 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2021 | 20 | 0.170 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 83 | 0.170 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2021 | 1 | 0.170 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2021 | 1 | 0.170 |
Why?
|
| Heart Injuries | 1 | 2021 | 1 | 0.170 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2021 | 1 | 0.170 |
Why?
|
| Embolism, Paradoxical | 1 | 2021 | 1 | 0.170 |
Why?
|
| Foramen Ovale, Patent | 1 | 2021 | 1 | 0.170 |
Why?
|
| Thromboembolism | 1 | 2021 | 2 | 0.170 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 14 | 0.170 |
Why?
|
| Pediatrics | 1 | 2021 | 6 | 0.170 |
Why?
|
| Stroke | 1 | 2021 | 48 | 0.160 |
Why?
|
| Hypertension | 1 | 2021 | 58 | 0.160 |
Why?
|
| Mutation | 1 | 2021 | 132 | 0.160 |
Why?
|
| Infant, Newborn | 3 | 2024 | 48 | 0.150 |
Why?
|
| Young Adult | 4 | 2024 | 787 | 0.150 |
Why?
|
| Pandemics | 3 | 2023 | 73 | 0.140 |
Why?
|
| Risk Factors | 3 | 2023 | 159 | 0.130 |
Why?
|
| Birth Weight | 2 | 2024 | 3 | 0.100 |
Why?
|
| Coronary Angiography | 2 | 2023 | 5 | 0.100 |
Why?
|
| Coronary Vessels | 2 | 2023 | 27 | 0.100 |
Why?
|
| Epithelium | 2 | 2024 | 9 | 0.100 |
Why?
|
| Rats | 2 | 2024 | 241 | 0.090 |
Why?
|
| Hospitals | 2 | 2022 | 10 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2023 | 177 | 0.090 |
Why?
|
| Kidney | 2 | 2022 | 51 | 0.090 |
Why?
|
| Electric Impedance | 2 | 2021 | 16 | 0.090 |
Why?
|
| Heart | 2 | 2021 | 48 | 0.080 |
Why?
|
| Child | 2 | 2023 | 627 | 0.070 |
Why?
|
| Animals | 2 | 2024 | 1711 | 0.070 |
Why?
|
| Consensus | 1 | 2024 | 12 | 0.060 |
Why?
|
| Precision Medicine | 1 | 2024 | 10 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2024 | 16 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 20 | 0.050 |
Why?
|
| Urinary Bladder Diseases | 1 | 2024 | 1 | 0.050 |
Why?
|
| Cecal Diseases | 1 | 2024 | 1 | 0.050 |
Why?
|
| Ovarian Diseases | 1 | 2024 | 1 | 0.050 |
Why?
|
| Ureteral Diseases | 1 | 2024 | 1 | 0.050 |
Why?
|
| Operative Time | 1 | 2024 | 1 | 0.050 |
Why?
|
| Ureter | 1 | 2024 | 2 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2024 | 6 | 0.050 |
Why?
|
| Myoblasts, Cardiac | 1 | 2024 | 1 | 0.050 |
Why?
|
| Cardiomegaly | 1 | 2024 | 4 | 0.050 |
Why?
|
| Somites | 1 | 2024 | 1 | 0.050 |
Why?
|
| Myocardial Contraction | 1 | 2024 | 6 | 0.050 |
Why?
|
| Cell Line | 1 | 2024 | 84 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2024 | 37 | 0.050 |
Why?
|
| Fertilization in Vitro | 1 | 2023 | 2 | 0.050 |
Why?
|
| Probability | 1 | 2023 | 11 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2024 | 40 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2023 | 1 | 0.050 |
Why?
|
| Aftercare | 1 | 2023 | 6 | 0.050 |
Why?
|
| Disease Management | 1 | 2023 | 4 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2023 | 32 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2023 | 18 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 12 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2023 | 34 | 0.050 |
Why?
|
| Lipid Peroxides | 1 | 2022 | 1 | 0.050 |
Why?
|
| Return to Sport | 1 | 2022 | 2 | 0.050 |
Why?
|
| Europe | 1 | 2022 | 2 | 0.050 |
Why?
|
| Inflammation | 1 | 2023 | 57 | 0.050 |
Why?
|
| Athletes | 1 | 2022 | 8 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2023 | 75 | 0.050 |
Why?
|
| Embryo Transfer | 1 | 2022 | 1 | 0.050 |
Why?
|
| Pregnancy Rate | 1 | 2022 | 1 | 0.050 |
Why?
|
| Chest Pain | 1 | 2022 | 1 | 0.050 |
Why?
|
| Conservative Treatment | 1 | 2022 | 1 | 0.050 |
Why?
|
| Dysmenorrhea | 1 | 2022 | 1 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2022 | 3 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 3 | 0.050 |
Why?
|
| Anastomosis, Surgical | 1 | 2022 | 3 | 0.050 |
Why?
|
| Coronary Circulation | 1 | 2022 | 6 | 0.050 |
Why?
|
| Microcirculation | 1 | 2022 | 7 | 0.050 |
Why?
|
| Phenotype | 1 | 2022 | 67 | 0.050 |
Why?
|
| Dyspnea | 1 | 2022 | 1 | 0.050 |
Why?
|
| Cephalosporins | 1 | 2022 | 13 | 0.050 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2022 | 1 | 0.050 |
Why?
|
| Papillary Muscles | 1 | 2022 | 1 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2022 | 10 | 0.050 |
Why?
|
| Adolescent Health | 1 | 2022 | 1 | 0.050 |
Why?
|
| Hypoxia | 1 | 2022 | 8 | 0.050 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2022 | 4 | 0.050 |
Why?
|
| Ventricular Remodeling | 1 | 2021 | 2 | 0.050 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2021 | 8 | 0.050 |
Why?
|
| Oxygen Consumption | 1 | 2022 | 23 | 0.050 |
Why?
|
| Heart Ventricles | 1 | 2022 | 21 | 0.050 |
Why?
|
| Ethanol | 1 | 2022 | 45 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2022 | 10 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 30 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2022 | 26 | 0.040 |
Why?
|
| Obesity | 1 | 2023 | 115 | 0.040 |
Why?
|
| Registries | 1 | 2022 | 22 | 0.040 |
Why?
|
| Exercise Test | 1 | 2022 | 41 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2021 | 18 | 0.040 |
Why?
|
| Electronics | 1 | 2021 | 15 | 0.040 |
Why?
|
| Logistic Models | 1 | 2022 | 64 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2021 | 13 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 41 | 0.040 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 1 | 0.040 |
Why?
|
| Syndrome | 1 | 2021 | 5 | 0.040 |
Why?
|
| Prealbumin | 1 | 2021 | 1 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2021 | 1 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2021 | 6 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2021 | 4 | 0.040 |
Why?
|
| Troponin T | 1 | 2021 | 1 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 102 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 19 | 0.040 |
Why?
|
| Cardiac Catheterization | 1 | 2021 | 3 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 5 | 0.040 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2021 | 3 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 6 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2021 | 25 | 0.040 |
Why?
|
| Echocardiography | 1 | 2021 | 9 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 269 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 23 | 0.040 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2021 | 1 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2021 | 2 | 0.040 |
Why?
|
| Age Factors | 1 | 2021 | 65 | 0.040 |
Why?
|
| Lung | 1 | 2021 | 35 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2020 | 5 | 0.040 |
Why?
|
| Aortic Valve | 1 | 2020 | 4 | 0.040 |
Why?
|
| Sex Factors | 1 | 2021 | 76 | 0.040 |
Why?
|
| Biomarkers | 1 | 2021 | 81 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2021 | 40 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 176 | 0.040 |
Why?
|